Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
Clinical trial NCT01467492 · TERMINATED
Trial details
- NCT number
- NCT01467492
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- TERMINATED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2012-01-01
- Primary completion
- 2014-05-01
- Enrollment
- 121
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.